Accès ouvert

Viraemia and HIV drug resistance among people receiving dolutegravir versus efavirenz-based first-line antiretroviral therapy

Article scientifique 2023 Anglais

Résumé

SUMMARY Limited data exists to inform management of viraemia among people receiving dolutegravir-based first-line ART in low- and middle-income countries. Among South-Africans with viraemia ≥1000copies/mL receiving dolutegravir (n=43) and efavirenz (n=37), we found no dolutegravir resistance, but high efavirenz resistance (66.7%). 12-week resuppression was higher with dolutegravir (85%) versus efavirenz (38%).

Citer ce document

Dorward, J., Sookrajh, Y., Lessells, R., Bulo, E., Bodley, N., Singh, L., Moodley, P., Samsunder, N., Drain, P., Hayward, G., Butler, C., Garrett, N. (2023). Viraemia and HIV drug resistance among people receiving dolutegravir versus efavirenz-based first-line antiretroviral therapy. https://doi.org/10.1101/2023.06.16.23291523

Accès au document

Texte intégral en lecture en ligne, réservé aux abonnés SPHAERO et aux membres de l'institution. Se connecter

Auteur(s)

Jienchi Dorward Yukteshwar Sookrajh Richard Lessells Elliot Bulo Nicola Bodley Lavanya Singh Pravi Moodley Natasha Samsunder Paul K. Drain Gail Hayward Christopher Butler Nigel Garrett

Statistiques

Consultations : 1

Téléchargements : 0